MeiraGTx Holdings plc Amortization of Debt Discount (Premium)
MeiraGTx Holdings plc (MGTX) reported Amortization of Debt Discount (Premium) of $663.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-13
- MeiraGTx Holdings plc amortization of debt discount (premium) for the quarter ending 2026-06-30 was $435.00K, a 56.47% increase year-over-year.
- MeiraGTx Holdings plc amortization of debt discount (premium) for the quarter ending 2026-03-31 was $228.00K, a 16.79% decline year-over-year.
- MeiraGTx Holdings plc amortization of debt discount (premium) for the quarter ending 2025-12-31 was $283.00K, a 1.43% increase year-over-year.
- MeiraGTx Holdings plc amortization of debt discount (premium) for the quarter ending 2025-09-30 was $282.00K, a 1.44% increase year-over-year.
- MeiraGTx Holdings plc amortization of debt discount (premium) for fiscal 2025 was $1.12M, a 1.27% increase from fiscal 2024.
- MeiraGTx Holdings plc amortization of debt discount (premium) for fiscal 2024 was $1.10M, a 1.85% increase from fiscal 2023.
- MeiraGTx Holdings plc amortization of debt discount (premium) for fiscal 2023 was $1.08M, a 143.92% increase from fiscal 2022.
- MeiraGTx Holdings plc amortization of debt discount (premium) for fiscal 2022 was $444.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $663.00K 10-Q · filed 2026-08-13 | $946.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $228.00K 10-Q · filed 2026-05-14 | $511.00K derived: sum of 2 quarters · filed 2026-05-14 | $793.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $565.00K derived: sum of 2 quarters · filed 2026-03-30 | $843.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.12M 10-K · filed 2026-03-30 |
| 2025-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $560.00K derived: sum of 2 quarters · filed 2026-08-13 | $834.00K 10-Q · filed 2025-11-13 | $1.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $552.00K 10-Q · filed 2026-08-13 | $831.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $274.00K 10-Q · filed 2026-05-14 | $553.00K derived: sum of 2 quarters · filed 2026-05-14 | $831.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.10M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $557.00K derived: sum of 2 quarters · filed 2026-03-30 | $830.00K derived: sum of 3 quarters · filed 2026-03-30 | $1.10M 10-K · filed 2026-03-30 |
| 2024-09-30 | $278.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $551.00K derived: sum of 2 quarters · filed 2025-11-13 | $824.00K 10-Q · filed 2025-11-13 | $1.10M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $546.00K 10-Q · filed 2025-08-14 | $820.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.09M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $273.00K 10-Q · filed 2025-05-13 | $547.00K derived: sum of 2 quarters · filed 2025-05-13 | $818.00K derived: sum of 3 quarters · filed 2025-05-13 | $1.09M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $545.00K derived: sum of 2 quarters · filed 2025-03-13 | $817.00K derived: sum of 3 quarters · filed 2025-03-13 | $1.08M 10-K · filed 2025-03-13 |
| 2023-09-30 | $271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $543.00K derived: sum of 2 quarters · filed 2024-11-13 | $809.00K 10-Q · filed 2024-11-13 | $1.08M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $272.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $538.00K 10-Q · filed 2024-08-12 | $812.00K derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | $266.00K 10-Q · filed 2024-05-09 | $540.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $444.00K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $170.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |